Hannah Dry

937 total citations
12 papers, 295 citations indexed

About

Hannah Dry is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Hannah Dry has authored 12 papers receiving a total of 295 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Molecular Biology and 2 papers in Surgery. Recurrent topics in Hannah Dry's work include Cancer Immunotherapy and Biomarkers (4 papers), HER2/EGFR in Cancer Research (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Hannah Dry is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), HER2/EGFR in Cancer Research (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Hannah Dry collaborates with scholars based in United Kingdom, United States and South Korea. Hannah Dry's co-authors include Darren A.E. Cross, Sylvie M. Guichard, B. R. Davies, Dario R. Alessi, Eeva Sommer, Ross Stewart, Vatsala Karwe, Peter Schmid, Seock‐Ah Im and Ana T. Nunes and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Hannah Dry

12 papers receiving 292 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hannah Dry United Kingdom	6	166	143	48	45	42	12	295
Eric Haines United States	9	144 0.9×	167 1.2×	25 0.5×	44 1.0×	28 0.7×	14	282
Woody Han United States	6	141 0.8×	188 1.3×	24 0.5×	77 1.7×	25 0.6×	8	345
Colin Mooney United States	6	188 1.1×	139 1.0×	60 1.3×	58 1.3×	18 0.4×	9	461
Megan M. Starr United States	4	180 1.1×	181 1.3×	19 0.4×	98 2.2×	57 1.4×	4	335
Melanie Dujka United States	7	122 0.7×	223 1.6×	40 0.8×	44 1.0×	16 0.4×	12	344
Seog Young Kim South Korea	7	203 1.2×	129 0.9×	19 0.4×	33 0.7×	56 1.3×	9	327
Beatrix Jahnke Germany	7	202 1.2×	184 1.3×	50 1.0×	22 0.5×	17 0.4×	8	328
Anita Welk Germany	6	175 1.1×	154 1.1×	22 0.5×	51 1.1×	24 0.6×	7	321
Hyung-Seok Hur South Korea	5	203 1.2×	204 1.4×	19 0.4×	71 1.6×	35 0.8×	6	315
Flavia Barbi Italy	6	185 1.1×	240 1.7×	44 0.9×	15 0.3×	32 0.8×	6	500

Countries citing papers authored by Hannah Dry

Since Specialization

Citations

This map shows the geographic impact of Hannah Dry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hannah Dry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hannah Dry more than expected).

Fields of papers citing papers by Hannah Dry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hannah Dry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hannah Dry. The network helps show where Hannah Dry may publish in the future.

Co-authorship network of co-authors of Hannah Dry

This figure shows the co-authorship network connecting the top 25 collaborators of Hannah Dry. A scholar is included among the top collaborators of Hannah Dry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hannah Dry. Hannah Dry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Willis, Brandon S., Hannah Dry, Wendan Xu, et al.. (2024). Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma. Leukemia. 38(12). 2663–2674. 2 indexed citations

Bardia, Aditya, Lajos Pusztai, Kathy S. Albain, et al.. (2024). TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Therapeutic Advances in Medical Oncology. 16. 12693072–12693072. 16 indexed citations

Monk, Bradley J., Takafumi Toita, Xiaohua Wu, et al.. (2022). O001/#504 Durvalumab, in combination with and following chemoradiotherapy, in locally advanced cervical cancer: results from the phase 3 international, randomized, double-blind, placebo-controlled calla trial. YUHSpace (Yonsei University Medical Library). A2–A3. 10 indexed citations

Schmid, Peter, Zbigniew Nowecki, Seock‐Ah Im, et al.. (2022). Abstract PD10-03: BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC): Results from Arm 1 D + paclitaxel (P), Arm 2 D+P + capivasertib (C), and Arm 5 D+P + oleclumab (O). Cancer Research. 82(4_Supplement). PD10–3. 3 indexed citations

Rosenberg, Jonathan E., Se Hoon Park, Vadim Kozlov, et al.. (2022). Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU). Journal of Clinical Oncology. 41(1). 43–53. 32 indexed citations

Rosenberg, Jonathan E., Se Hoon Park, Tu Van Dao, et al.. (2022). BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC).. Journal of Clinical Oncology. 40(6_suppl). 437–437. 17 indexed citations

Schmid, Peter, et al.. (2021). BEGONIA: Phase 1b/2, open-label, platform study of the safety and efficacy of durvalumab (D) ± paclitaxel (P) with novel oncology therapies for first-line metastatic triple-negative breast cancer (mTNBC): Addition of arm 7, D + datopotamab deruxtecan (Dato-DXd; DS-1062).. Journal of Clinical Oncology. 39(15_suppl). TPS1105–TPS1105. 3 indexed citations

Schmid, Peter, Seock‐Ah Im, Anne Armstrong, et al.. (2021). BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).. Journal of Clinical Oncology. 39(15_suppl). 1023–1023. 79 indexed citations

Willis, Brandon S., Hannah Dry, Wendan Xu, et al.. (2021). Combination Benefit of Capivasertib and Venetoclax in Preclinical Models of Diffuse Large B-Cell Lymphoma. Blood. 138(Supplement 1). 1870–1870. 1 indexed citations

10.

Barlaam, Bernard, Scott Boiko, Scott Boyd, et al.. (2020). Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors. Bioorganic & Medicinal Chemistry Letters. 30(22). 127523–127523. 3 indexed citations

11.

Hancox, Urs J., Sabina Cosulich, Hannah Dry, et al.. (2013). Abstract 3264: AZD8186: a potent selective inhibitor of PI3Kβ targeting PTEN-deficient tumours dependent on dysregulated PI3Kβ signalling.. Cancer Research. 73(8_Supplement). 3264–3264. 2 indexed citations

12.

Sommer, Eeva, Hannah Dry, Darren A.E. Cross, et al.. (2013). Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors. Biochemical Journal. 452(3). 499–508. 127 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact